Chronic Leukemias

A collection of features and news articles published in ASH Clinical News related to chronic leukemias.

On location

Functional, Nutritional, and Social Status Predict Survival Outcomes in Older Patients With CLL

Geriatric domains of functional status, social activity, and nutritional status were associated with overall survival (OS) and progression-free survival (PFS) in older adults with...
On location

Head-to-Head Trial Confirms Acalabrutinib’s Noninferiority to Ibrutinib in CLL

At EHA2021 Virtual, researchers presented results from the first head-to-head trial of Bruton tyrosine kinase (BTK) inhibitors in chronic lymphocytic leukemia (CLL), finding that...
On location

Evaluating Maintenance Therapy After Fixed-Duration Obinutuzumab Plus Venetoclax in CLL

For patients with chronic lymphocytic leukemia (CLL) who are considered unfit for FCR chemotherapy (fludarabine, cyclophosphamide, rituximab), a fixed-duration regimen of venetoclax plus obinutuzumab...

Exploring Venetoclax Plus Azacitidine in CMML and MPNs

The combination of the BCL2 inhibitor venetoclax and the hypomethylating agent azacitidine has been established as a standard of care for patients with acute...
On location

Fixed-Duration Ibrutinib, Venetoclax Oral Combination Effective in CLL/SLL

A fixed-duration regimen of first-line ibrutinib plus venetoclax provided deep, durable responses in patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), according to...
How I Treat In Brief

Venetoclax-Based Treatments for Chronic Lymphocytic Leukemia

William G. Wierda, MD, PhD, and Francesco Paolo Tambaro, MD, PhD, review the role of venetoclax and other targeted therapies in the treatment of...
WIB_icon

Evaluating Ibrutinib in Patients With Heavily Pretreated Hairy Cell Leukemia

Treatment with ibrutinib offered durable disease control in patients with heavily pretreated classic and variant relapsed hairy cell leukemia (HCL) who were not expected...
WIB_icon

Acalabrutinib Induces Durable Remission in Patients With Treatment Naïve Chronic Lymphocytic Leukemia

Treatment with the next-generation covalent Bruton tyrosine kinase (BTK) inhibitor acalabrutinib was safe and led to durable, long-term remission in a small group of...

Trilaciclib Approved for Chemotherapy-Induced Myelosuppression

The U.S. Food and Drug Administration (FDA) has approved trilaciclib, a cyclin-dependent kinase 4/6 inhibitor, to reduce the frequency of bone marrow suppression in...

FDA Grants Breakthrough Therapy Designation to Asciminib for CML

The FDA has granted breakthrough therapy designation to asciminib, a first-in-class allosteric inhibitor specifically targeting the ABL myristoyl pocket (STAMP), for the treatment of...